Ok thanks.
Interesting to think really what that means when you extrapolate.
If all 4 are successful then according to E&P you are sitting at $45.90. By the time December 24 / Jan 25 comes around, we will also be sitting on an additional 4 quarters of revenue, so you could mount an argument that we could be sitting around the $50 mark.
What value attaches to 4 successful Phase 3 trials and what would that mean for the SP? What value attaches to Autism at large and what would that mean for the SP? What value attaches to and rumours of a takeover?
Interesting food for thought!
I am starting to revise my TO price upwards quite considerably.
Neuren Media and Analyst Coverage, page-749
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.86 |
Change
0.560(2.90%) |
Mkt cap ! $2.538B | |||
| Open | High | Low | Value | Volume |
| $19.80 | $20.00 | $19.40 | $3.777M | 191.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1060 | $19.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.87 | 209 | 1 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |